On Sunday, Crown Prince Mohammed bin Salman welcomed Syria’s new interim president, Ahmed al-Sharaa, in Riyadh. Barely three months ago, Riyadh had hosted former president Bashar al-Assad, now in ...
Republican attorneys-general from more than a dozen US states have accused BlackRock, Goldman Sachs and JPMorgan of misrepresenting the risks of investing in China, including the possibility of a ...
The rising cost of support for people with long-term health conditions — set to rise to a staggering £100bn by 2029-30 in cash terms on current projections — has become a huge source of pressure on ...
Iman will soon seek to assert control of his private patriarchy. The story has the air of fable, but plays bold games with convention. A gun appears early, before a dark, droll twist on the usual ...
Irish rural drama Bring Them Down pursues an inexorable logic of retribution and calamity, like a primal Western with a streak of Jacobean tragedy. Offsetting this is a narrative sophistication that ...
Her specialism is occasionwear from the big French designers, and she has one of the most extensive collections of vintage Chanel out of any vintage shop in Paris (the brand’s Foundation recently came ...
Moonlight’ director Barry Jenkins pens Rachel Morrison’s impressive debut about Olympic champion Claressa ‘T-Rex’ Shields ...
Marks and Spencer has appointed the former head of Boohoo to run its clothing, home and beauty divisions as the retailer presses ahead with its turnaround.
Trump administration move to temporarily shutter US agency triggers crisis for independent outlets in ex-Soviet space ...
It has also diversified geographically — limiting the impact of tax loophole closures. The US accounts for less than half of Temu’s global GMV, compared with 100 per cent three years ago, when the app ...
Yet GSK is clearly healing from its multiple comorbidities — the worst of which was the (now largely resolved) legal overhang related to heartburn medicine Zantac. Chief executive Emma Walmsley also ...
The world’s biggest drugmaker Eli Lilly has forecast that profits for the year will beat expectations, after two choppy quarters when disappointing sales of its blockbuster weight-loss drugs led to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results